Impact of an Echographic Algorithm on Hemodynamic Optimization in the First 4 Days of Septic Shock Management
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Sep 12, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how using a special ultrasound technique called echocardiography can help manage fluids in patients who are experiencing septic shock. Septic shock is a serious condition that occurs when an infection leads to dangerously low blood pressure and can cause organ failure. The trial aims to find out if this echocardiographic approach can improve how doctors manage fluids during the first four days of treatment, which is crucial since both too much and too little fluid can be harmful.
To participate in the trial, patients must be at least 18 years old and currently in an intensive care unit, having developed septic shock. They will also need to give consent, either themselves or through a trusted person. Before joining, each patient will undergo a heart ultrasound to ensure they meet the study's health criteria. Participants can expect close monitoring and care during this critical period, and this research could help improve treatment for future patients facing similar challenges.
Gender
ALL
Eligibility criteria
- • All eligible patients will have a cardiac echocardiogram prior to inclusion for the sole purpose of eliminating special situations that are part of the non-inclusion criteria listed below.
- • Inclusion Criteria
- • Patient in an intensive care unit who develops septic shock on admission or during hospitalization, as defined by SEPSIS-3 criteria.
- • Patient or trusted person / legal representative / family member / curator / guardian who has given free and informed consent and has signed the consent form or patient included in an emergency situation.
- • Patient affiliated or beneficiary of a health insurance plan.
- • Patient at least (≥) 18 years of age.
- Exclusion Criteria:
- • Refusal of consent.
- • Patient under court protection or guardianship.
- • Moribund patient with a life expectancy of less than 48 hours.
- • Non-echogenic patient.
- • Cardiac tamponade.
- • Infective endocarditis.
- • Intracavitary thrombus.
- • Dilated cardiomyopathy with LVEF (Left Ventricular Ejection Fraction\<40%.
- • Parturient or nursing patient.
About Centre Hospitalier Universitaire De Nīmes
The Centre Hospitalier Universitaire de Nîmes (CHU Nîmes) is a leading academic medical center located in Nîmes, France, dedicated to advancing healthcare through innovative clinical research and patient care. As a prominent sponsor of clinical trials, CHU Nîmes collaborates with a multidisciplinary team of healthcare professionals and researchers to conduct rigorous studies aimed at improving treatment outcomes and enhancing medical knowledge across various specialties. With a strong commitment to ethical standards and patient safety, CHU Nîmes fosters a research environment that encourages scientific excellence and contributes to the development of new therapies and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nîmes, , France
Patients applied
Trial Officials
Claire Roger
Principal Investigator
CHU Nimes
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported